Effect of Acyclovir on HIV-1 Set Point among Herpes Simplex Virus Type 2-Seropositive Persons during Early HIV-1 Infection

被引：9

作者：

Kim, H. Nina ^{[1
,4
]}

Wang, Jing ^{[7
]}

Hughes, James ^{[7
]}

Coombs, Robert ^{[2
,4
,5
]}

Sanchez, Jorge ^{[11
]}

Reid, Stewart ^{[8
,12
]}

Delany-Moretlwe, Sinead ^{[13
]}

Cowan, Frances ^{[14
]}

Fuchs, Jonathan ^{[9
,11
]}

Eshleman, Susan H. ^{[10
]}

Khaki, Leila ^{[7
]}

McMahon, Moira A. ^{[10
]}

Siliciano, Robert F. ^{[10
]}

Wald, Anna ^{[4
,7
]}

Celum, Connie ^{[3
,4
,6
]}

机构：

[1] Univ Washington, Harborview Med Ctr, Sch Med, Dept Med, Seattle, WA 98104 USA

[2] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98104 USA

[3] Univ Washington, Sch Med, Dept Global Hlth, Seattle, WA 98104 USA

[4] Univ Washington, Sch Publ Hlth, Dept Med, Seattle, WA 98104 USA

[5] Univ Washington, Sch Publ Hlth, Dept Lab Med, Seattle, WA 98104 USA

[6] Univ Washington, Sch Publ Hlth, Dept Global Hlth, Seattle, WA 98104 USA

[7] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA

[8] Univ Alabama, Dept Med, Birmingham, AL 35294 USA

[9] San Francisco Dept Publ Hlth, San Francisco, CA USA

[10] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA

[11] Asociac Civil Impacta Salud & Educ IMPACTA, Lima, Peru

[12] Ctr Infect Dis Res Zambia, Lusaka, Zambia

[13] Univ Witwatersrand, Reprod Hlth Unit, Johannesburg, South Africa

[14] UCL, London, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2010年 / 202卷 / 05期

基金：

美国国家卫生研究院;

关键词：

REVERSE-TRANSCRIPTASE; SEROCONVERSION; ACQUISITION; RESISTANCE; MUTATION; COHORT; UGANDA; TRIAL; RAKAI; MEN;

D O I：

10.1086/655662

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (Pp. 30) or CD4 cell counts (Pp. 85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.

引用

页码：734 / 738

页数：5

共 50 条

[31] Detection of a new variant of herpes simplex virus type 2 among HIV-1-infected individuals
Burrel, Sonia
Abrao, Emiliana P.
Desire, Nathalie
Seang, Sophie
Caumes, Eric
Agut, Henri
Boutolleau, David
JOURNAL OF CLINICAL VIROLOGY, 2013, 57 (03) : 267 - 269
[32] Herpes simplex virus type 2 and HIV infection among US military personnel: implications for health prevention programmes
Bautista, C. T.
Singer, D. E.
O'Connell, R. J.
Crum-Cianflone, N.
Agan, B. K.
Malia, J. A.
Sanchez, J. L.
Peel, S. A.
Michael, N. L.
Scott, P. T.
INTERNATIONAL JOURNAL OF STD & AIDS, 2009, 20 (09) : 634 - 637
[33] Pseudotyping of HIV-1 with Human T-Lymphotropic Virus 1 (HTLV-1) Envelope Glycoprotein during HIV-1-HTLV-1 Coinfection Facilitates Direct HIV-1 Infection of Female Genital Epithelial Cells: Implications for Sexual Transmission of HIV-1
Tang, Yuyang
George, Alvin M.
Petrechko, Oksana
Nouvet, Franklin J.
Sweet, Stephanie D.
Tanaka, Yuetsu
Imbiakha, Brian S.
Jiang, Guochun
Gao, Wei
Anastos, Kathryn
Hildreth, James E. K.
MSPHERE, 2018, 3 (02)
[34] The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
AIDS, 1998, 12 (05) : F9 - F14
[35] Performance of a Modified In-House HIV-1 Avidity Assay among a Cohort of Newly Diagnosed HIV-1 Infected Individuals and the Effect of ART on the Maturation of HIV-1 Specific Antibodies
Alex, Diviya
Williams, Tennison Inba Raj
Sachithanandham, Jaiprasath
Prasannakumar, Swaminathan
Demosthenes, John Paul
Ramalingam, Veena Vadhini
Victor, Punitha John
Rupali, Priscilla
Fletcher, Gnanadurai John
Kannangai, Rajesh
CURRENT HIV RESEARCH, 2019, 17 (02) : 134 - 145
[36] Effect of HIV-1 infection and increasing immunosuppression on menstrual function
Ezechi, Oliver C.
Jogo, Andrea
Gab-Okafor, Chidinma
Onwujekwe, Dan I.
Ezeobi, Paschal M.
Gbajabiamila, Titi
Adu, Rosemary A.
Audu, Rosemary A.
Musa, Adesola Z.
Salu, Olumuyiwa B.
Meschack, Emily
Herbertson, Ebiere
Odunukwe, Nkiru
Idigbe, Oni E.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (05) : 1053 - 1058
[37] Chronic herpes simplex virus type-2 infection and HIV viral load
Duffus, WA
Mermin, J
Bunnell, R
Byers, RH
Odongo, G
Ekwaru, P
Downing, R
INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (11) : 733 - 735
[38] Comparative evaluation of Aptima HIV-1 Qualitative RNA assay performance using plasma and serum specimens from persons with established HIV-1 infection
Ethridge, Steven F.
Wesolowski, Laura G.
Nasrullah, Muazzam
Kennedy, M. Susan
Delaney, Kevin P.
Candal, Debra
Owen, S. Michele
JOURNAL OF CLINICAL VIROLOGY, 2011, 52 : S63 - S66
[39] Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
Michaelis, Martin
Kleinschmidt, Malte C.
Bojkova, Denisa
Rabenau, Holger F.
Wass, Mark N.
Cinatl, Jindrich, Jr.
FRONTIERS IN MICROBIOLOGY, 2019, 10
[40] Viral load differences in early infection with two HIV-1 subtypes
Hu, DJ
Vanichseni, S
Mastro, TD
Raktham, S
Young, NL
Mock, PA
Subbarao, S
Parekh, BS
Srisuwanvilai, L
Sutthent, R
Wasi, C
Heneine, W
Choopanya, K
AIDS, 2001, 15 (06) : 683 - 691

← 1 2 3 4 5 →